We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
News

Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting

Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
News

Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Santhera Pharmaceuticals has announced that results from the RHODOS study evaluating the efficacy of Catena® in Leber Hereditary Optic Neuropathy (LHON) will be presented at the 21st Meeting of the European Neurological Society in Lisbon, Portugal.

The presentation entitled A Randomized, Placebo-Controlled Trial of Idebenone in Leber's Hereditary Optic Neuropathy will be given on May 30, 2011 at 16:00 CET.

Data will be presented by the co-principal investigator, Professor Thomas Klopstock from the Friedrich-Baur-Institut at the Department of Neurology, University of Munich, Germany.

The results from the RHODOS study show that Catena® can protect the vision of patients, who are at highest risk of vision loss, and enhance the recovery of visual acuity in severely affected patients.

These data are supported by secondary, clinically meaningful efficacy variables such as color contrast sensitivity, changes in retinal nerve fiber layer thickness and clinical benefit.

In the study, Catena® showed consistent clinically relevant superiority over placebo. Santhera will file a Marketing Authorization Application with the European Medicines Agency in the first half of 2011.

Advertisement